Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications
X Zhong, X He, Y Wang, Z Hu, H Huang, S Zhao… - Journal of hematology & …, 2022 - Springer
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
cancer-related death worldwide. Countless CRC patients undergo disease progression. As …
cancer-related death worldwide. Countless CRC patients undergo disease progression. As …
The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Background: The albumin levels may potentially be used as a prognostic biomarker in
patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close …
patients with cancertreated with immune checkpoint inhibitors (ICIs) due to its close …
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
S Serratì, M Guida, R Di Fonte, S De Summa… - Molecular Cancer, 2022 - Springer
Background The immunotherapy with immune checkpoints inhibitors (ICI) has changed the
life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not …
life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not …
The predictive potential of the baseline C-reactive protein levels for the efficiency of immune checkpoint inhibitors in cancer patients: a systematic review and meta …
CL Han, GX Meng, ZN Ding, ZR Dong… - Frontiers in …, 2022 - frontiersin.org
Background The relationship between baseline C-reactive protein (CRP) level and the
prognosis of cancer patients receiving immune checkpoint inhibitor (ICI) treatment remains …
prognosis of cancer patients receiving immune checkpoint inhibitor (ICI) treatment remains …
[HTML][HTML] Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?
E Splendiani, ZM Besharat, A Covre, M Maio… - Pharmacology & …, 2024 - Elsevier
Melanoma is the most aggressive form of skin cancer, representing approximately 4% of all
cutaneous neoplasms it accounts for up to 80% of deaths. Advanced stages of melanoma …
cutaneous neoplasms it accounts for up to 80% of deaths. Advanced stages of melanoma …
[HTML][HTML] Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review
LS Ter Maat, IAJ van Duin, SG Elias… - European Journal of …, 2022 - Elsevier
Background Checkpoint inhibition has radically improved the perspective for patients with
metastatic cancer, but predicting who will not respond with high certainty remains difficult …
metastatic cancer, but predicting who will not respond with high certainty remains difficult …
[HTML][HTML] Computer-aided detection and segmentation of malignant melanoma lesions on whole-body 18F-FDG PET/CT using an interpretable deep learning approach
I Dirks, M Keyaerts, B Neyns… - Computer methods and …, 2022 - Elsevier
Background and objective: In oncology, 18-fluorodeoxyglucose (18 F-FDG) positron
emission tomography (PET)/computed tomography (CT) is widely used to identify and …
emission tomography (PET)/computed tomography (CT) is widely used to identify and …
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy
Y Gao, C Wu, X Chen, L Ma, X Zhang, J Chen… - Frontiers in …, 2022 - frontiersin.org
Cancer immunotherapy, especially immune-checkpoint inhibitors (ICIs), has paved a new
way for the treatment of many types of malignancies, particularly advanced-stage cancers …
way for the treatment of many types of malignancies, particularly advanced-stage cancers …
Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy
A Nicolini, P Ferrari - Frontiers in Immunology, 2024 - frontiersin.org
Metabolic reprogramming is akey hallmark of tumors, developed in response to hypoxia and
nutrient deficiency during tumor progression. In both cancer and immune cells, there is a …
nutrient deficiency during tumor progression. In both cancer and immune cells, there is a …
Anti-PD-1: when to stop treatment
Y Jansen, AAM van der Veldt, G Awada… - Current oncology reports, 2022 - Springer
Abstract Purpose of Review Emerging data indicate that immune checkpoint blockade (ICB)
in patients with metastatic melanoma can be stopped electively or at the time of toxicity with …
in patients with metastatic melanoma can be stopped electively or at the time of toxicity with …